Truist Financial Issues Positive Forecast for Janux Therapeutics (NASDAQ:JANX) Stock Price

by · The Cerbat Gem

Janux Therapeutics (NASDAQ:JANX – Free Report) had its price target upped by Truist Financial from $26.00 to $27.00 in a research report released on Friday,Benzinga reports. They currently have a buy rating on the stock.

JANX has been the subject of several other reports. Barclays raised their target price on Janux Therapeutics from $14.00 to $15.00 and gave the company an “underweight” rating in a research note on Friday. HC Wainwright reiterated a “buy” rating on shares of Janux Therapeutics in a report on Monday, October 19th. Weiss Ratings restated a “sell (d-)” rating on shares of Janux Therapeutics in a report on Friday, October 16th. Guggenheim lowered their target price on Janux Therapeutics from $58.00 to $55.00 and set a “buy” rating on the stock in a research report on Friday, August 7th. Finally, Stifel Nicolaus set a $35.00 target price on Janux Therapeutics in a research report on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $36.92.

Read Our Latest Stock Analysis on Janux Therapeutics

Janux Therapeutics Trading Up 9.8%

NASDAQ JANX traded up $1.57 on Friday, hitting $17.63. 852,234 shares of the company were exchanged, compared to its average volume of 769,690. The company has a market cap of $1.08 billion, a PE ratio of -11.09 and a beta of 2.44. Janux Therapeutics has a 12 month low of $12.12 and a 12 month high of $35.34. The stock has a fifty day moving average of $17.49 and a 200-day moving average of $15.42.

Janux Therapeutics (NASDAQ:JANX – Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.47) by $0.13. The company had revenue of $9.29 million during the quarter, compared to the consensus estimate of $8.03 million. On average, analysts expect that Janux Therapeutics will post -1.70 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. purchased a new stake in Janux Therapeutics in the second quarter worth $94,228,000. State Street Corp lifted its position in shares of Janux Therapeutics by 22.0% during the 2nd quarter. State Street Corp now owns 3,004,899 shares of the company’s stock valued at $46,155,000 after buying an additional 540,882 shares during the last quarter. Alyeska Investment Group L.P. increased its stake in shares of Janux Therapeutics by 2.9% in the second quarter. Alyeska Investment Group L.P. now owns 1,647,140 shares of the company’s stock worth $25,300,000 after purchasing an additional 46,051 shares in the last quarter. Algert Global LLC raised its holdings in Janux Therapeutics by 150.5% during the 2nd quarter. Algert Global LLC now owns 1,110,889 shares of the company’s stock valued at $17,063,000 after acquiring an additional 667,492 shares during the period. Finally, Bank of America Corp DE purchased a new stake in Janux Therapeutics during the 2nd quarter worth about $13,985,000. 75.39% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Janux Therapeutics

Here are the key news stories impacting Janux Therapeutics this week:

  • Positive Sentiment: Wedbush raised its price target to $40 from $36 and reiterated its outperform rating, implying substantial upside from the cited $17.63 share price. Wedbush raises Janux price target
  • Positive Sentiment: Truist raised its target to $27 from $26 and maintained a buy rating, signaling continued confidence in JANX. Truist analyst recommendations
  • Positive Sentiment: Janux reported a third-quarter loss of $0.34 per share, narrower than analysts’ expected loss of $0.45–$0.47. Revenue of $9.29 million also exceeded the $8.03 million estimate. The results beat expectations, although the company remained loss-making. Janux third-quarter 2026 results
  • Neutral Sentiment: Janux said it dosed the first patient in the Phase 1 study of JANX013 in combination with JANX007, marking progress in its clinical pipeline; the update does not establish how the treatment will perform. Janux business highlights
  • Negative Sentiment: Barclays raised its target only to $15 from $14 but kept an underweight rating, placing its target below the cited share price and underscoring a bearish view that contrasts with other analysts. Barclays analyst recommendations

About Janux Therapeutics

(Get Free Report)

Janux Therapeutics, Inc is a clinical-stage biopharmaceutical company developing immune-based medicines for the treatment of cancer and autoimmune diseases. The company’s research is focused on designing therapies that selectively activate the immune system in diseased tissue while limiting activity in healthy tissue.

Janux’s proprietary technology platform is designed to create tumor-activated T-cell engager therapies and other immunomodulators. These medicines are engineered to remain relatively inactive in the circulation and become activated in the tumor microenvironment, with the goal of improving the therapeutic window of immune therapies.

Featured Articles